RxDoctor Payments Data

Stuart Ruch, MD

Cardiovascular Disease · Hyannis, MANPI 1750489241

Payments from drug & device makers

$666in general payments, 2019–2025

Across 38 payments — averaging $17.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi-aventis U.S. LLC$176
  • E.r. Squibb & Sons, L.L.C.$89
  • Johnson & Johnson$67
  • Esperion Therapeutics, Inc.$57
  • Boehringer Ingelheim$51
  • Abbott$49
  • plus $176 from 7 others

What the payments were for

  • Food & beverage$666100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$666 in reported general payments places this provider in the 35th percentile of 750 cardiovascular disease providers in Massachusetts.

See all cardiovascular disease providers in Massachusetts

Medicare billing

Part B allowed, 2024
$107,681
Medicare patients
1,435
Services billed
2,260

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban279$236,883
XareltoRivaroxaban89$82,547
EntrestoSacubitril/Valsartan30$33,715
Repatha SureclickEvolocumab14$11,146
Praluent PenAlirocumab19$9,717
Rosuvastatin Calcium219$8,899
Metoprolol Succinate340$6,209
Atorvastatin Calcium282$3,607
Dofetilide11$3,183
Valsartan74$2,247
Ezetimibe34$1,580
Amiodarone Hcl33$1,341
Varenicline Tartrate14$956
Amlodipine Besylate111$952
ClopidogrelClopidogrel Bisulfate62$918

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$27$236,883279 claims
Johnson & JohnsonXarelto$67$82,54789 claims
NovartisEntresto$14$33,71530 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 750 cardiovascular disease providers in Massachusetts.

Other cardiovascular disease in Hyannis

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →